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nerves. Of the sacral spinal nerves, S3 is the most practical
one for use in chronic electrical stimulation.8 Unilateral
sacral segmental nerve stimulation by an S3 electrode may
offer a non-destructive treatment alternative. Encouraged
by favourable results obtained in patients with urge
incontinence due to idiopathic detrusor instability,9 we
determined the feasibility of this treatment in a pilot study
in which patients were followed for at least 2 years.
Methods
About 130 MS patients are seen regularly in our neuro-urology
outpatient service. Those who were refractory to conservative
treatment and dissatisfied with their urge incontinence were
offered the option of sacral segmental nerve stimulation if the
following inclusion criteria were met: 1) patients had to have
urodynamic evidence of detrusor hyperreflexia and a functional
bladder capacity of at least 150 mL, based on a voiding diary
and/or urodynamic study; 2) a diagnosis of MS10 had to be
confirmed by an experienced neurologist; and 3) the disease had to
be stable or only slowly progressing. The baseline work-up
included history and physical examination, urinalysis, urine
cytology, plain abdominal radiograph, ultrasound examination of
the kidneys, cystoscopy, two 4-day voiding/incontinence diaries,
and medium-rate filling and voiding video-urodynamic studies.
The methods, units, and definitions in relation to the urodynamic
studies conform to the standards recommended by the
International Continence Society.11 Six patients met the inclusion
criteria. They signed an informed consent form and underwent
further testing. The characteristics of these women are summarised
in table 1.
Acute percutaneous nerve evaluation
Under local anaesthesia a sheathed 22-gauge spinal needle is
inserted in the left and the right S3 sacral foramina leaving only the
tip of the needle uninsulated. Electrical current is applied to the
needle in a graduated fashion until a visual muscle response is
obtained. This is done with an external nerve stimulator (Screener
3625, Medtronic, USA; frequency 10 Hz; pulsewidth 210 ms;
amplitude adjustable within a range of 0·5–20 mA). The use of low
amplitude and short (210 ms) stimuli ensures preferential
depolarisation of larger myelinated nerve fibres.7 The thin and
unmyelinated pain fibres and autonomic fibres are not activated.
During stimulation the patients perceive a slight pulling sensation
near the rectum which extends towards the labia. The muscle
response associated with S3 stimulation is a bellows-like inward
Summary
Background Urge urinary incontinence in multiple sclerosis
patients is usually due to detrusor hyperreflexia. Patients
who do not respond to conservative measures such as
anticholinergics, with or without clean intermittent
catheterisation, are difficult to manage.
Methods We applied electrical stimulation to the S3 sacral
spinal nerves with the aim of activating afferent somatic
nerve fibres. Stimulation of these fibres can inhibit the
micturition reflex. An S3 electrode coupled to a
subcutaneously placed pulse generator was implanted in four
women who had shown a good response during temporary
stimulation via a percutaneously placed wire electrode. All
patients were followed for at least 2 years.
Findings The number of leakage episodes decreased from a
mean of 4 to 0·3 per 24 h. Two patients were completely
dry. The hyperreflexia disappeared in one, improved in two,
and got worse in one patient. The urodynamic result in the
last patient may be explained by clinical progression of the
multiple sclerosis.
Interpretation Chronic stimulation of the S3 sacral spinal
nerve by an implantable neuroprosthesis is a promising
treatment option for selected multiple sclerosis patients with
refractory urge incontinence.
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Introduction
Incontinence in multiple sclerosis (MS) patients is usually
due to detrusor hyperreflexia. The commonest cause of
hyperreflexia in MS is spinal pathology.1 In cats, when a
spinal lesion interrupts the spinobulbospinal pathways of
the micturition reflex, a new sacral segmental reflex arc
may become functional as a result of neuroplasticity.2 The
afferent neurons of this reflex are unmyelinated C-fibres
which serve as the afferent arc for detrusor hyperreflexia. In
incontinent MS patients, who are refractory to conservative
treatment with anticholinergic drugs3 with or without clean
intermittent catheterisation, destructive therapies, such as
intravesical instillations of capsaicin,4 bladder transsection,
transvesical phenol injection of the pelvic plexus,
augmentation ileocystoplasty, and even urinary diversion,
have been advocated with varying success.5
Vodusek et al6,7 have shown that electrical stimulation of
non-muscular sacral somatic nerve afferents can induce
bladder inhibition in patients with detrusor hyperreflexia
due to traumatic spinal cord injury or MS. Most of these
fibres reach the spinal cord via the dorsal roots of the sacral
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Early reports
Patient Age Time since Disability History of Urodynamic
(yr) MS diagnosis (EDSS) incontinence diagnosis
(yr) (yr)
1 53 14 Walks with frame 12 DHR
(6·0)
2 42 12 Walks abnormally 3 DHR+DSD
(4·0)
3 39 8 Chair-bound (7·0) 6 DHR+DSD
4 53 14 Chair-bound (7·5) 4 DHR+DSD
5 57 24 Walks with sticks 9 DHR+DSD
(6·0)
6 24 5 Walks abnormally 2 DHR
(4·0)
DHR=detrusor hyperreflexia; DSD=detrusor sphincter dyssynergia; EDSS=Expanded
disability status scale.14
Table 1: Characteristics of patients who met the inclusion
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movement of the levator ani muscle and plantar flexion of the great
toe. This response acts as a biological indicator of correct needle
position and of nerve integrity. Apart from the efferent somatic
(motor) nerve fibres innervating the pelvic floor muscles, afferent
somatic (sensory) nerve fibres are stimulated (invisibly) with the
aim of inhibiting the micturition reflex.
Subchronic test stimulation
An electrode (3–0 flexon pacer wire, Becton and Dickinson) was
placed in the S3 foramen giving the best pelvic floor muscle
response to stimulation. Good muscle responses on one or both
sides were found in all patients. The electrode was connected to
the external nerve stimulator and left in situ for 5 days. The
patients were instructed to keep the stimulation on continuously
and to keep another voiding/incontinence diary. Patients with a
greater than 50% reduction in pad use and/or number of leakages
were considered eligible for a permanent implant provided the
symptoms recurred after removal of the test electrode.
Permanent electrode implant
The implant consists of a Pisces Quad 3886 foramen lead
connected, via a 7495 extension lead, to an Itrel II 7424 pulse
generator (Medtronic, Kerkrade, the Netherlands), placed
subcutaneously in the lower abdomen. The lead is fixed in the
foramen that showed a successful result during the test. The
stimulation can be adjusted telemetrically.
Follow-up tests included regular voiding/incontinence diaries
and urodynamic studies which were done 6 months after
implantation with electrical stimulation on.
Results
All six patients were women. In patient 5 (table 1) it was
not possible to place a temporary electrode due to obesity.
Of the five women who completed the test period, four
responded with a greater than 50% reduction and one with
a 20% reduction in pad use and/or leakage episodes. A
permanent electrode was not implanted in this last patient
(patient 6). Although, on occasion, she had voided volumes
of up to 160 mL, her cystometric capacity was only 115
mL. Her more severe hyperreflexia than patients 1–5 may
explain her limited response. The duration of follow-up in
the patients with permanent electrodes is shown in table 2.
The initial stimulation parameters after activation of the
pulse generator were as follows: pulse width 210 ms,
frequency 10 Hz, mean amplitude 2·8 (SE 0·4) volts. After
6 months the amplitude had increased to 3·4 (0·4) volts
and the optimum amplitude at last follow-up was 4·2 (0·3)
volts. It was not necessary to use drugs with an action on
the lower urinary tract during follow-up.
The symptomatic results of S3 sacral spinal nerve
stimulation are summarised in table 2. The number of
leakage episodes decreased from a mean of 4 to 0·3 per
24 h. Two patients were completely dry. In all patients the
improvements in the number of leakage episodes were
stable at long-term follow-up and even slightly better than
that found during the test period.
The urodynamic data at 6 months follow-up are
summarised in table 3. The hyperreflexia disappeared in
patient 3. In patient 1 the volume at first and at maximum
hyperreflexic contraction as well as the bladder capacity
increased; in patient 2 the amplitudes of the hyperreflexic
contractions clearly decreased. In patient 4 the urodynamic
situation deteriorated. There have been no complications.
Discussion
Our results show that treatment of refractory urge
incontinence by chronic S3 sacral spinal nerve stimulation
is feasible in selected MS patients.
An explanation for the effectiveness of this treatment in
detrusor hyperreflexia is based on animal experiments and
electrophysiological studies in human beings. Spinal
inhibitory systems capable of interrupting a detrusor
contraction can be activated by electrical stimulation of
afferent anorectal branches of the pelvic nerve, afferent
non-muscular somatic (sensory) fibres in the pudendal
nerve, and muscle afferents from the limbs.6,7,12 These fibres
pass through the sacral spinal nerves. Afferents from the
pelvic floor muscles are without an inhibitory effect on the
bladder, at least in the cat.13
All six patients were women, who generally have more to
gain from being dry than men since there are no good
collection devices for women. In three of our four patients
the urodynamic results were in agreement with the voiding
diary results, although complete disappearance of detrusor
hyperreflexia does not seem to be a prerequisite for an
excellent symptomatic result. The provocative nature of
Patient 1 Patient 2 Patient 3 Patient 4
No of pads used per 24 h
Pre 3·2 3·7 4·6 6·0
Test 1·8 2·0 0·6 2·7
6 mo 0 1·5 0 0
Last 2·3 1·7 0 0
No of leakage episodes
per 24 h
Pre 3·9 3·4 6·5 4·7
Test 1·0 1·3 1·1 0·3
6 mo 0 0·5 0 0
Last 0·3 0·7 0 0
Voiding frequency
per 24 h
Pre 11·8* 18·8 13·2* 15·0
Test 11·3* 10·4 11·3* 8·0
6 mo 11·4* 11·3 6·3* 10·3
Last 14·0* 10·4 8·3* 10·6
Mean voided volume per
micturition (mL)
Pre 140 82 119 193
Test 119 94 307 178
6 mo 189 126 379 113
Last 128 125 380 88
*Voiding frequency includes spontaneous micturition and intermittent self-
catheterisations. †Patient 1 followed up for 39 mo, patient 2 for 38 mo, patient 3 for
35 mo and patient 4 for 24 mo.
Table 2: Results of voiding/incontinence diary measures
comparing pre treatment (pre) with subchronic test period
(test), 6 months, and last follow-up (last)†
Patient 1 Patient 2 Patient 3 Patient 4
Bladder volume (mL) at
1st hyperreflexic contraction
Pre 440 195 175 210
6 mo 405 328 — 106
Amplitude (cm H2O) of
1st hyperreflexic contraction
Pre 32 32 48 14
6 mo 18 46 — 34
Bladder volume (mL) at
maximum hyperreflexic
contraction
Pre 460 201 175 267
6 mo 452 331 — 155
Amplitude (cm H2O) of
maximum hyperreflexic
contraction
Pre 56 35 48 14
6 mo 25 46 — 29
Bladder capacity (mL)
Pre 478 201 177 267
6 mo 452 331 490 157
—No hyperreflexia present. Follow-up urodynamic studies were done with electrical
stimulation on.
Table 3: Urodynamic data before implant (pre) and 6 months
after implant
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Summary
Background The surface molecule named Fas/CD95, which
is expressed on activated lymphocytes, can trigger cell
death following interaction with its ligand (Fas L). This Fas-
Fas-L interaction is thought to be a major regulatory
mechanism for controlling the life span of peripheral
lymphocytes, and therefore autoimmunity.
Methods We assessed clinical, immunological and
pathological features in three children who inherited
mutations of the Fas-encoding gene. One infant had a
genomic homozygous deletion, while two siblings had a
heterozygous mutation in the fas gene.
Findings The patient with a complete lack of Fas protein
expression had prenatal onset of massive
lymphoproliferation, which involved the spleen, the liver, and
the intrathoracic and abdominal lymph nodes.
Lymphoproliferation mainly involved T cells negative for the
CD4 and CD8 receptors. These cells, which had a high
mitotic index, were essentially found in the T cell zones of
lymphoid organs. Active cell division was indicated by a rapid
rise in the lymphocyte count following a chemotherapy-
induced reduction in the lymphocyte burden. Despite the
total Fas protein deficiency, limited autoimmunity was found
in this child at age 1 year. A lymphoproliferative syndrome
with similar characteristics—but less intense than in the
patient with complete Fas deficiency—also occurred from a
young age in the siblings with a fas gene mutation on one
allele only. One sibling developed neutropoenia, autoimmune
haemolytic anaemia, and severe recurrent thrombo-
cytopoenia.
Interpretation Fas-deficiency causes a non-malignant
syndrome characterised by the accumulation of dividing
lymphocytes. Severity of disease is probably related to the
degree of functional Fas deficiency. Heterozygous fas gene
mutations, like homozygous deletions, can also be expressed
in various cells and tissues and may predispose towards
autoimmune disorders. Fas deficiency should be considered
in children with enlarged peripheral lymphoid organs and
hyperimmunoglobulinaemia, and sometimes the occurrence
of autoimmune manifestations towards blood cells.
Lancet 1996; 348: 719–23
Introduction
The Fas/CD 95/Apo-1 molecule, originally described with
two monoclonal antibodies (anti-Fas, anti-APO-1) that
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standard medium-fill urodynamic tests as opposed to
natural filling could be an explanation for this discrepancy.
In patient 4 symptomatic improvement was good although
urodynamically the situation had deteriorated. The
symptomatic improvement in this patient can be explained
by a decreased 24 h voided volume which shows that she
had changed her drinking habits. This may have been due
to increasing apathy, which characterised the clinical
progression of the MS in this patient. The progression
started about 6 months after the implant.
Patients should be cautioned that the clinical picture of
MS often evolves in an unpredictable way and that
progression of the disease may jeopardise the long-term
result. The low complication rate and the urodynamic and
durable clinical effects achieved support the soundness of
this approach and show that it is worthwhile to continue to
explore this treatment option in selected MS patients. The
fact that no irreversible changes to the bladder or nerves
occur is an advantage of this treatment option over
destructive alternatives. Before general acceptance, longer
follow-up is needed as well as studies comparing groups of
patients randomly assigned to implantation or no treatment
to assess possible spontaneous improvements.
This study was supported by a grant from the Health Insurance Board of the
Netherlands (Ziekenfondsraad; OGP 90-005).
References
1 Betts CD, D’Mellow MT, Fowler CJ. Urinary symptoms and the
neurological features of bladder dysfunction in multiple sclerosis. 
J Neurol Neurosurg Psychiatry 1993; 56: 245–50.
2 De Groat WC, Kawatani T, Hisamitsu T, et al. Mechanisms underlying
the recovery of urinary bladder function following spinal cord injury.
J Auton Nerv Syst 1990; 30: S71–78.
3 Urinary Incontinence Guideline Panel. Urinary incontinence in adults:
clinical practice guidelines. Rockville, MD, USA: Agency for health care
policy and research, 1992: 38–43, no 92-0038.
4 Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical
capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg
Psychiatry 1994; 57: 169–73.
5 Mundy AR. The unstable bladder. Urol Clin North Am 1985; 12:
317–28.
6 Vodusek DB, Light JK, Libby JM. Detrusor inhibition induced by
stimulation of pudendal nerve afferents. Neurourol Urodyn 1986; 5:
381–89.
7 Vodusek DB, Plevnik S, Janez J, Vrtacnik P. Detrusor inhibition on
selective pudendal nerve stimulation in the perineum. Neurourol Urodyn
1988; 6: 389–93.
8 Schmidt RA, Senn E, Tangho EA. Functional evaluation of sacral nerve
root integrity. Urology 1990; 35: 388–92.
9 Bosch JLHR, Groen J. Sacral (S3) segmental nerve stimulation as a
treatment for urge-incontinence in patients with detrusor instability:
results of chronic electrical stimulation using an implantable
neuroprosthesis. J Urol 1995; 154: 504–07.
10 Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for
multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;
13: 227–31.
11 Abrams PH, Blaivas JG, Stanton SL, Andersen JT. Standardisation of
terminology of lower urinary tract function. In: Krane RJ, Siroky MB,
eds. Clinical Neurourology. Boston, Little Brown 1991: 651–69.
12 Fall M, Lindström S. Electrical stimulation: a physiologic approach to
the treatment of urinary incontinence. Urol Clin N Am 1991; 18:
393–407.
13 Lindström S, Sudsuang R. Functionally specific bladder reflexes from
pelvic and pudendal nerve branches: an experimental study in the cat.
Neurourol Urodyn 1989; 8: 392–93.
14 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52.
